china releases digital currency Top searches

Food stocks fell at the beginning of the day, and food stocks fell at the beginning, and food stocks fell at the beginning, and Jialong shares, Anji Food, Huang Shanghuang, three squirrels, and Barbie Foods followed suit.Zongheng Communication established a new science and technology company in Zhejiang. The enterprise search APP shows that recently, Zongheng Cross-border Technology (Zhejiang) Co., Ltd. was established with Xu Shasha as its legal representative and a registered capital of 10 million yuan. Its business scope includes: sales of information security equipment; Network equipment sales; Internet of things technical services, etc. Enterprise equity penetration shows that the company is wholly owned by Zongheng Communication.FTSE China A50 index futures opened 0.80% lower, and closed down 0.89% in the last session.

Kangxinuo said on the interactive platform that the company is promoting the research and development of a variety of innovative vaccines, submitting applications for related matters in accordance with the guiding principles of CDE, and actively communicating and reporting.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.The United States said that the ceasefire agreement in Gaza was close to being reached, but Hamas didn't respond. On the 12th local time, Sullivan, Assistant to the President of the United States for National Security Affairs, held talks with Israeli Prime Minister Benjamin Netanyahu. After the talks, Sullivan told the media that he thought Netanyahu was ready to reach a ceasefire agreement with Palestinian Islamic Resistance Movement (Hamas). According to US media reports on the 12th, sources said that the negotiating position of Palestinian Islamic Resistance Movement (Hamas) has softened, and it may agree to the temporary presence of Israeli troops in the Gaza after the ceasefire. However, Hamas has not yet responded to this news.

Xray, an important partner of Yizhizhuang, officially announced a strategic cooperation with Google. According to Yizhizhuang, at the Android XR conference held in new york, Google officially announced a strategic cooperation with Xray to jointly build the Android XR ecosystem. This cooperation not only highlights XREAL's position as the world's largest manufacturer of AR glasses, but also marks a new stage of accelerated popularization of XR industry. It is noteworthy that Lingyizhi, as a long-term strategic partner of XREAL, provides key components and assembly services for XREAL AR glasses.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.The Hang Seng Index and Hang Seng Technology Index both fell more than 1%.